Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KY-0118 in advanced solid tumors
NCT06175780Phase 1Recruiting
- Sponsor
- Novatim Immune Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of KY-0118 in solid tumor (3 arms), sponsored by Novatim Immune Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days and Adverse Events. Started Dec 2022; status: recruiting.
02
Drugs
KY-0118
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06175780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175780.